63% of millennials and 61% of Gen Zers feel more connected to health brands since starting GLP-1s, per a January Dentsu report.
The news: Novo Nordisk is partnering with WeightWatchers to offer discounted Wegovy to cash-pay customers. Our take: WeightWatchers is recognizing that diet culture is being replaced by weight loss medications accessible via virtual care. To stand out from other Novo’s other telehealth partners, WeightWatchers should lean into marketing that positions the company as a pioneer weight loss brand that’s now meeting consumer demand for GLP-1s.
The news: Consumers who are more familiar with AI are also more likely to mistrust an AI-assisted diagnosis from their doctor, per a recently published Journal of Medical Internet Research survey. Our take: Physicians and healthcare marketers can’t assume people who are familiar with AI will be more comfortable with AI uses in healthcare. Marketers need to talk about AI as a tool with many positive effects like freeing doctors for longer personal interactions and resulting in fewer mistakes.
The trend: US consumers trust the pharma companies that advertise the prescription drugs they’re taking. Our take: Pharma companies can take heart in knowing the people who take their drugs trust them and their advertising. But it’s also an opportunity for precise data and media targeting to reach new consumers who would be interested in their medication—undiagnosed people or competitors’ patients—and receptive to learning about them.
The trend: Over three-quarters of US hospitals now task pharmacists with patient care responsibilities, according to a recently published survey from the American Society of Health System Pharmacists. Our take: Struggling retail pharmacies should also entrust pharmacists to play a bigger role in patient care, especially as some drugstores pivot to health-focused store formats.
The news: A majority of GLP-1 weight loss drug consumers are now staying on the medications for more than a year, per an annual Prime Therapeutics analysis. The Prime study includes 5,780 people via healthcare claims over three years; the mean age was 47 and 80% were women. The final word: Adherence rates longer than a year validates the idea that prescription weight loss GLP-1s, and newer drugs on the way, are here to stay as chronic disease treatments. It shifts typical weight loss marketing from cyclical—keep your New Year’s resolution or lose weight for your wedding—to medical and consistent.
The news: Novo Nordisk is terminating its short-lived partnership with Hims & Hers. The drugmaker is accusing Hims of illegally selling knockoff versions of Wegovy, while deceptively marketing its compounded GLP-1 products. Our take: Hims will likely regret its refusal to cooperate with Novo and Eli Lilly, who have taken control of the D2C weight loss drug market.
The news: Gilead’s long-lasting injection for HIV prevention received FDA approval, but the breakthrough drug comes with a high price tag ($28,218 annual list price). The takeaway: Another breakthrough drug with a high price tag adds fuel to the long-held idea that pharma puts profits over patients. Drugmakers need to offer and advertise practical solutions, such as direct financial help, and will need to fund more nonprofit programs to change perceptions.
The news: Prescription drug approval timelines will shrink under an FDA pilot program that will reduce the approval timelines from a typical 10 months to just 1 to 2 months. Our take: Speedier reviews and new AI programs for drug developers are good ideas, but pharma companies should remember the COVID-19 vaccines speed-to-market backlash and weigh the time benefit against whether their drugs will gain trust with physicians and patients.
The trend: Women see and hear more health-related information than men, especially when it comes to weight loss drugs and anti-aging treatments. Our take: Pharma and healthcare marketers need to more effectively reach women. Instead of marketing to all women, market to mindsets like self-care via social media influencers’ tips and advice, or motivations like caregiving and prevention by tapping into mammogram screening advocacy and resources that support overburdened women who care for loved ones.
The data: Nearly two-thirds of US adults (64%) have an unfavorable view of the House’s One Big Beautiful Bill Act, per KFF polling. Our take: If they aren’t already, healthcare marketers ought to be launching blitz campaigns about the bill’s potential ramifications. For instance, they could put pressure on lawmakers in the Senate by citing just-released study estimates that the proposed changes to Medicaid may result in ~25,000 preventable deaths annually due to how many patients will lose their physician, forgo needed medications, and put off screenings like mammograms.
The news: Anne Wojcicki, the co-founder and CEO of 23andMe, is set to recoup control of the company after outbidding Regeneron Pharmaceuticals in a bankruptcy action. Our take: 23andMe will have a brand reputation problem assuming Wojcicki regains control. The company’s best path forward, considering past mistakes, is tapping into new consumer health and wellness categories rather than enterprise partnerships with pharma.
The news: Novo Nordisk missed an important patent filing deadline in Canada for its weight loss and diabetes drug semaglutide, opening the door to generics as soon as next year. Our take: If Sandoz and other generic makers start selling semaglutide GLP-1 drugs in Canada next year, FDA approval for states may not matter. If drugmakers do start selling generic GLP-1s in Canada, Novo will see Ozempic brand sales drop, but the GLP-1 market could see a generics’ explosion.
The news: Novo Nordisk is partnering with AI drug discovery company Deep Apple Therapeutics to discover and develop new cardiometabolic drugs, including for obesity. The takeaway: Novo is not the biggest loser in the GLP-1 weight loss category, but it’s trailing Lilly in drug effectiveness, market value, and more importantly public perception. It’s critical for Novo to come up with new and better weight loss drugs—hence the deal with Deep Apple—but also polish its brand with consumers. A new CEO and new marketing direction could garner Novo some much-needed cachet.
The news: Eli Lilly said it won’t partner with telehealth companies that sell compounded weight loss drugs. Our take: Lilly’s demand may signal that it’s in a better position in the weight loss drug market than Novo to play hardball with industry partners such as Hims & Hers.
The news: BioNTech is buying cancer vaccine researcher and one-time COVID-19 vaccine rival CureVac in a $1.25 billion all-stock deal. The takeaway: The new HHS is taking a less-than-positive view on mainstream vaccines and mRNA technology, but it’s also signaled strong interest in personalized medicines and novel therapies. That’s good news for BioNTech, and could be a sign to other pharmas and biotechs that precision and specialty drugs are poised for fast tracking, while vaccines caught up in public and political controversy will be overscrutinized and delayed to market.
The news: GoodRx is rolling out a subscription service for erectile dysfunction (ED) treatment. Our take: GoodRx is in a great position to compete with the top D2C telehealth players since consumers are already on the site or app searching for prescription drug discounts—it has over 6 million active monthly consumers who use a coupon code. GoodRx might also be more trusted than pure-play telehealth companies in the eyes of consumers since its services help people save money on their healthcare.
The news: TikTok tweens and teens who make popular “Get ready with me” skincare routine videos may be harming their skin. The takeaway: Amid the closer social media scrutiny, skincare health brands should be clear about products that are not made for young skin. Social media teams need to be aware and proactive when interacting with tween and teen content creators.
The news: Avidity Biosciences struck a deal with the FDA for accelerated approval of a treatment for a rare type of muscular dystrophy. Our take: The Avidity announcement and federal health agency enthusiasm are positive signs for biotech and pharma companies looking for accelerated approval for rare disease candidates. Federal authorities and drugmakers will need to balance speed-to-market with rigorous science to ensure physician and consumer confidence.
The news: Digital health startup Virta Health is guaranteeing that its employer and health plan customers won’t increase spending on GLP-1 drugs for their members. Our take: Virta’s financial guarantee will likely catch the attention of employers and insurers, but it could quickly backfire from a financial perspective if it’s unable to curb GLP-1 prescription volume.